Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Nov;8(21):1337.
doi: 10.21037/atm-20-3389.

Tivozanib for hepatocellular carcinoma: not likely a new option

Florian Estrade  1 , Fanny Le Du  1 , Laurence Crouzet  1 , Héloïse Bourien  1 , Léa Muzellec  1 , Julien Edeline  1
Affiliations
Editorial

Tivozanib for hepatocellular carcinoma: not likely a new option

Florian Estrade et al. Ann Transl Med. 2020 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm-20-3389). JE reports personal fees from Bayer, personal fees from Eisai, personal fees from Roche, personal fees from MSD, personal fees from AstraZeneca, grants and personal fees from BMS, grants from Beigene, personal fees from Ipsen, during the conduct of the study; grants and personal fees from BTG, outside the submitted work. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Fitzmaurice C, Abate D, Abbasi N, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol 2019;5:1749-68. 10.1001/jamaoncol.2019.2996 - DOI - PMC - PubMed
    1. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. 10.1056/NEJMoa0708857 - DOI - PubMed
    1. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34. 10.1016/S1470-2045(08)70285-7 - DOI - PubMed
    1. Kudo M, Finn RS, Qin S, et al. Lenvatinib versussorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-73. 10.1016/S0140-6736(18)30207-1 - DOI - PubMed
    1. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018;379:54-63. 10.1056/NEJMoa1717002 - DOI - PMC - PubMed

LinkOut - more resources